Elisabeth Roider joins Maximon as a Partner & Chief Scientific and Medical Officer

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

Maximon boosts its leadership with Harvard and Swiss trained excellence.

Dr Elisabeth Roider, who is dedicated to bringing the field of longevity to the next level, has joined the Swiss-based longevity company builder Maximon as Partner and Chief Scientific and Medical Officer.

Longevity.Technology: Elisabeth Roider, MD, PhD, MBA, is a Harvard- and Swiss-trained, internationally renowned physician scientist. As a physician-scientist, she works at the University Hospital of Basel and the Harvard Medical School. Her work has resulted in various high-impact publications, patents and awards.

Driven by the mission to identify and solve the most relevant medical and public health problems, Roider joins Maximon as a Partner & Chief Scientific and Medical Officer.

“Longevity science is exciting but for multiple reasons highly under investigated,” she says. With the help of Maximon and private investors, I am eager to drive innovation to the next level to see what the distant future will look like.”

READ MORE: Launchpad for longevity investment and networking

Roider’s aim is to support scientists and physicians in transforming true innovation into solid solutions and products, helping patients and consumers to achieve better, healthier – and finally, longer – lives.

She adds: “I love life, I love science, I love people. Together with Maximon’s outstanding team I am excited to allow more people to enjoy a long, healthy, and fulfilled life.”

We’ll be finding out more about Elisabeth Roider’s goals at Maximon in a couple of weeks – stay tuned!

Eleanor Garth

Editor

Now a science and medicine journalist, Eleanor worked as a consultant for university spin-out companies and provided research support at Imperial College London and various London hospitals in a former life.

With a keen interest in all things geroscience, Eleanor covers the biological mechanisms of aging, highlighting how interventions – from nutritional strategies to advanced therapeutics – can influence the aging process at a cellular level. She also investigates the broader implications of aging research, including the integration of longevity science into healthcare strategy and the expanding wellness economy. Her work (hopefully) provides insights into how these developments are shaping the emerging landscape of healthspan optimization and age-related innovation.

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

Longevity investors put evidence to the test

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE